PRMDA: personalized recommendation-based MiRNA-disease association prediction

被引:17
作者
You, Zhu-Hong [1 ]
Wang, Luo-Pin [2 ]
Chen, Xing [3 ]
Zhang, Shanwen [1 ]
Li, Xiao-Fang [1 ]
Yan, Gui-Ying [4 ]
Li, Zheng-Wei [5 ]
机构
[1] Xijing Univ, Dept Informat Engn, Xian, Shaanxi, Peoples R China
[2] Wuhan Univ, Int Software Sch, Wuhan, Hubei, Peoples R China
[3] China Univ Min & Technol, Sch Informat & Control Engn, Xuzhou, Peoples R China
[4] Chinese Acad Sci, Acad Math & Syst Sci, Beijing, Peoples R China
[5] Sch Comp Sci & Technol, Hefei, Anhui, Peoples R China
基金
中国国家自然科学基金;
关键词
miRNA; disease; miRNA-disease association; personalized recommendation; TARGET INTERACTION PREDICTION; HUMAN MICRORNA; COLORECTAL-CANCER; DOWN-REGULATION; BREAST-CANCER; LUNG CANCERS; EXPRESSION; RNA; DATABASE; GROWTH;
D O I
10.18632/oncotarget.20996
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, researchers have been increasingly focusing on microRNAs ( miRNAs) with accumulating evidence indicating that miRNAs serve as a vital role in various biological processes and dysfunctions of miRNAs are closely related with human complex diseases. Predicting potential associations between miRNAs and diseases is attached considerable significance in the domains of biology, medicine, and bioinformatics. In this study, we developed a computational model of Personalized Recommendation-based MiRNA-Disease Association prediction (PRMDA) to predict potential related miRNA for all diseases by implementing personalized recommendation-based algorithm based on integrated similarity for diseases and miRNAs. PRMDA is a global method capable of prioritizing candidate miRNAs for all diseases simultaneously. Moreover, the model could be applied to diseases without any known associated miRNAs. PRMDA obtained AUC of 0.8315 based on leave-one-out cross validation, which demonstrated that PRMDA could be regarded as a reliable tool for miRNA-disease association prediction. Besides, we implemented PRMDA on the HMDD V1.0 and HMDD V2.0 databases for three kinds of case studies about five important human cancers in order to test the performance of the model from different perspectives. As a result, 92%, 94%, 88%, 96% and 88% out of the top 50 candidate miRNAs predicted by PRMDA for Colon Neoplasms, Esophageal Neoplasms, Lymphoma, Lung Neoplasms and Breast Neoplasms, respectively, were confirmed by experimental reports.
引用
收藏
页码:85568 / 85583
页数:16
相关论文
共 77 条
  • [1] microRNAs: Tiny regulators with great potential
    Ambros, V
    [J]. CELL, 2001, 107 (07) : 823 - 826
  • [2] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
  • [3] Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis
    Au, Sandy Leung-Kuen
    Wong, Carmen Chak-Lui
    Lee, Joyce Man-Fong
    Fan, Dorothy Ngo-Yin
    Tsang, Felice Hoching
    Ng, Irene Oi-Lin
    Wong, Chun-Ming
    [J]. HEPATOLOGY, 2012, 56 (02) : 622 - 631
  • [4] Bandyopadhyay Sanghamitra, 2010, Silence, V1, P6, DOI 10.1186/1758-907X-1-6
  • [5] MicroRNAs: Target Recognition and Regulatory Functions
    Bartel, David P.
    [J]. CELL, 2009, 136 (02) : 215 - 233
  • [6] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [7] MicroRNA signatures in human cancers
    Calin, George A.
    Croce, Carlo M.
    [J]. NATURE REVIEWS CANCER, 2006, 6 (11) : 857 - 866
  • [8] MUTATIONS THAT LEAD TO REITERATIONS IN THE CELL LINEAGES OF C-ELEGANS
    CHALFIE, M
    HORVITZ, HR
    SULSTON, JE
    [J]. CELL, 1981, 24 (01) : 59 - 69
  • [9] Long non-coding RNAs and complex diseases: from experimental results to computational models
    Chen, Xing
    Yan, Chenggang Clarence
    Zhang, Xu
    You, Zhu-Hong
    [J]. BRIEFINGS IN BIOINFORMATICS, 2017, 18 (04) : 558 - 576
  • [10] FMLNCSIM: fuzzy measure-based lncRNA functional similarity calculation model
    Chen, Xing
    Huang, Yu-An
    Wang, Xue-Song
    You, Zhu-Hong
    Chan, Keith C. C.
    [J]. ONCOTARGET, 2016, 7 (29) : 45948 - 45958